Access in all areas? A round up of developments in market access and health technology assessment: part 8
In this update, we discuss the pricing paradox of combination therapies in health technology assessment; examine the Inflation Reduction Act's impact on pharmaceutical innovation and analyze the revised Dutch economic evaluation guidelines.
Authors
- Sreeram V Ramagopalan (ORCID: https://orcid.org/0000-0002-5038-0916)
- Annie Jullien Pannelay
Institutions
- King's College London (GB)
- HighLife (France) (FR)
Publication Details
- Journal
- Journal of Comparative Effectiveness Research
- Published
- 2025-06-17
- DOI
- https://doi.org/10.57264/cer-2025-0091
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00